Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 197.43
CVM's Cash to Debt is ranked higher than
54% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. CVM: 197.43 )
Ranked among companies with meaningful Cash to Debt only.
CVM' s 10-Year Cash to Debt Range
Min: 0.4  Med: 579.00 Max: No Debt
Current: 197.43
Equity to Asset 0.03
CVM's Equity to Asset is ranked lower than
93% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CVM: 0.03 )
Ranked among companies with meaningful Equity to Asset only.
CVM' s 10-Year Equity to Asset Range
Min: -0.51  Med: 0.69 Max: 0.99
Current: 0.03
-0.51
0.99
F-Score: 3
Z-Score: -33.73
M-Score: -6.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -7915.99
CVM's Operating margin (%) is ranked lower than
92% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. CVM: -7915.99 )
Ranked among companies with meaningful Operating margin (%) only.
CVM' s 10-Year Operating margin (%) Range
Min: -190240  Med: -3316.49 Max: -928.57
Current: -7915.99
-190240
-928.57
Net-margin (%) -7175.89
CVM's Net-margin (%) is ranked lower than
92% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. CVM: -7175.89 )
Ranked among companies with meaningful Net-margin (%) only.
CVM' s 10-Year Net-margin (%) Range
Min: -154060  Med: -2772.17 Max: 6851.63
Current: -7175.89
-154060
6851.63
ROE (%) -333.94
CVM's ROE (%) is ranked lower than
95% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. CVM: -333.94 )
Ranked among companies with meaningful ROE (%) only.
CVM' s 10-Year ROE (%) Range
Min: -1352.47  Med: -130.93 Max: 48.78
Current: -333.94
-1352.47
48.78
ROA (%) -152.64
CVM's ROA (%) is ranked lower than
91% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. CVM: -152.64 )
Ranked among companies with meaningful ROA (%) only.
CVM' s 10-Year ROA (%) Range
Min: -238.89  Med: -79.20 Max: 25.01
Current: -152.64
-238.89
25.01
ROC (Joel Greenblatt) (%) -5490.64
CVM's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. CVM: -5490.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CVM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -6099.1  Med: -816.28 Max: 687.95
Current: -5490.64
-6099.1
687.95
Revenue Growth (3Y)(%) -100.00
CVM's Revenue Growth (3Y)(%) is ranked lower than
89% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. CVM: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CVM' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -32.50 Max: 39.2
Current: -100
0
39.2
EBITDA Growth (3Y)(%) -27.20
CVM's EBITDA Growth (3Y)(%) is ranked lower than
78% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. CVM: -27.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CVM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -51.7  Med: -12.60 Max: 17.2
Current: -27.2
-51.7
17.2
EPS Growth (3Y)(%) -26.90
CVM's EPS Growth (3Y)(%) is ranked lower than
75% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CVM: -26.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CVM' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3  Med: -17.60 Max: 44.7
Current: -26.9
-55.3
44.7
» CVM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CVM Guru Trades in

CVM Guru Trades in

Q4 2013

CVM Guru Trades in Q4 2013

Jim Simons 61,700 sh (New)
» More
Q1 2014

CVM Guru Trades in Q1 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CVM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.31
CVM's P/B is ranked higher than
54% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CVM: 4.31 )
Ranked among companies with meaningful P/B only.
CVM' s 10-Year P/B Range
Min: 1.54  Med: 12.81 Max: 53.55
Current: 4.31
1.54
53.55
Current Ratio 1.55
CVM's Current Ratio is ranked lower than
80% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CVM: 1.55 )
Ranked among companies with meaningful Current Ratio only.
CVM' s 10-Year Current Ratio Range
Min: 0.17  Med: 7.89 Max: 160
Current: 1.55
0.17
160
Quick Ratio 1.12
CVM's Quick Ratio is ranked lower than
82% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CVM: 1.12 )
Ranked among companies with meaningful Quick Ratio only.
CVM' s 10-Year Quick Ratio Range
Min: 0.04  Med: 7.85 Max: 160
Current: 1.12
0.04
160
Days Sales Outstanding 32.23
CVM's Days Sales Outstanding is ranked higher than
77% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CVM: 32.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVM' s 10-Year Days Sales Outstanding Range
Min: 23.58  Med: 91.25 Max: 365
Current: 32.23
23.58
365

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.31
CVM's Price/Tangible Book is ranked higher than
62% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CVM: 4.31 )
Ranked among companies with meaningful Price/Tangible Book only.
CVM' s 10-Year Price/Tangible Book Range
Min: 1.87  Med: 7.53 Max: 52.5
Current: 4.31
1.87
52.5
Earnings Yield (Greenblatt) (%) -62.05
CVM's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CVM: -62.05 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CVM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -64.07  Med: 0.00 Max: 0
Current: -62.05
-64.07
0

Analyst Estimate

Sep15 Sep16 Sep17 Sep18
Revenue(Mil) 1 1 2 2
EPS($) -0.40 -0.41 -0.34 0.34
EPS without NRI($) -0.40 -0.41 -0.34 0.34

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:LSRN.Germany,
CEL-SCI Corp was incorporated on March 22, 1983, in the state of Colorado. The Company is engaged in the research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. The Company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
» More Articles for CVM

Headlines

Articles On GuruFocus.com
Updated Coverage Report Focuses on CEL-SCI Corporation Jan 12 2015 
Coverage Initiation Report Focuses on CEL-SCI Corporation Oct 15 2014 
CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 

More From Other Websites
CEL-SCI Expands Its Phase I Study for Treatment of Anal Warts in HIV/HPV Co-Infected Patients with... Jul 20 2015
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 01 2015
CEL-SCI Reports June Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial Jul 01 2015
CEL SCI CORP Files SEC form 8-K, Change in Directors or Principal Officers Jun 30 2015
CEL-SCI Corporation (NYSE MKT: CVM), Arguably the Most Undervalued Phase III Biotech, is Updated in... Jun 29 2015
CEL SCI CORP Financials Jun 27 2015
CEL SCI CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 23 2015
NEW STORY CEL-SCI to Present at the 2015 Bio International Convention Jun 16 2015
CEL-SCI to Present at the 2015 BIO International Convention Jun 16 2015
NEW STORY CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial... Jun 08 2015
CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in... Jun 08 2015
CEL-SCI is Cleared to Start Patient Enrollment for Its Phase 3 Cancer Immunotherapy Trial in... Jun 08 2015
NEW STORY CEL-SCI Reports May Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial Jun 01 2015
CEL-SCI Reports May Patient Enrollment in Its Phase 3 Head and Neck Cancer Trial Jun 01 2015
NEW STORY CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $16 Million May 29 2015
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement May 29 2015
CEL-SCI Announces Closing of Public Offering for Gross Proceeds of $16 Million May 29 2015
NEW STORY CEL-SCI to Present at the 2015 Marcum MicroCap Conference May 27 2015
CEL-SCI to Present at the 2015 Marcum MicroCap Conference May 27 2015
CEL SCI CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... May 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK